Morning Movers 5/26: MAPP, CYTK, CMM, EMIS, UTHR Higher; SHLO, GM, CSIG, FSLR Lower

May 26, 2009 9:15 AM EDT

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) 133% HIGHER; announced that the efficacy portion of its first Phase 3 clinical trial evaluating its novel LEVADEX(TM) orally inhaled migraine therapy met all four primary endpoints. Additional endpoints showed that LEVADEX provided rapid and sustained pain relief for up to 48 hours after dosing.

Cytokinetics Inc. (Nasdaq: CYTK) 44.2% HIGHER; surging on news Amgen Inc. (Nasdaq: AMGN) exercised its option to obtain an exclusive license, worldwide (excluding Japan), to Cytokinetics' cardiac contractility program. The license includes CK-1827452, a novel cardiac myosin activator being developed for the treatment of heart failure. Click here for the full report.

China Mass Media Corp. (NYSE: CMM) 26.6% HIGHER; reports Q1 EPS of $0.37, versus the analyst estimate of $0.25. Revenue for the quarter was $21.9 million, versus the consensus of $18.40 million. Sees Q2 sales of $11.7-$13.9 million, versus the consensus of $16.40 million.

Shiloh Industries, Inc. (Nasdaq: SHLO) 18.4% LOWER; reports Q2 loss of $0.38, versus the analyst estimate of ($0.26). Revenue for the quarter was $62.2 million, versus the consensus of $70.50 million.

Emisphere Technologies, Inc. (NASDAQ: EMIS) 16.8% HIGHER; today announced data from a clinical study designed to assess the effect of oral administration of two peptides, GLP-1 and PYY3-36, utilizing Emisphere's Eligen(R) Technology on appetite suppression. Click here for the full report.

United Therapeutics Corporation (Nasdaq: UTHR) 8.2% HIGHER; announced that the FDA has approved ADCIRCA (tadalafil) tablets for oral administration, with a recommended dose of 40 mg, as the first once-daily phosphodiesterase type 5 inhibitor for the treatment of pulmonary arterial hypertension (PAH). ADCIRCA is indicated to improve exercise ability in WHO Group I PAH patients, which encompasses patients with multiple forms of PAH including etiologies such as idiopathic and familial PAH as well as PAH associated with scleroderma and congenital heart disease. Click here to see some comments from United's Chairman and CEO.

General Motors (NYSE: GM) 7.7% LOWER; continuing lower this week as the automaker's June 1st deadline approaches.

Canadian Solar (Nasdaq: CSIQ) 6.8% LOWER; reports Q1 loss of $0.10 per share, ex-items, above the consensus of a $0.26 loss. Revenues came in at $49.5 million, versus the consensus of $54.1 million. Click here for the full earnings report.

First Solar (Nasdaq: FSLR) 5.3% LOWER; FBR Capital downgrades the stock from Market Perform to Underperform and maintains their $110 price target, citing falling poly prices. Click here for the full report.

Get This Report Daily Here: http://www.streetinsider.com/entities/StreetInsider.com+Morning+Movers.

Related Categories

Special Reports

Stocks Mentioned

Related Entities

• StreetInsider.com Morning Movers

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?